Skip to content
Traceability first — every claim on this site is published only once substantiated
PEPTIDERESEARCH

Article 23 · 7 min

Melanocortin and neuropeptide receptor literature

MC1R to MC4R selectivity, and the neuropeptide research literature on Semax, Selank and related sequences.

The melanocortin receptor family

The melanocortin system is a family of peptide ligands and five G-protein-coupled receptors, MC1R through MC5R, with functions distributed across pigmentation, adrenal signalling, metabolism, autonomic regulation and other physiological systems. Endogenous ligands are derived largely from proopiomelanocortin, including alpha-, beta- and gamma-melanocyte-stimulating hormones and ACTH. Synthetic analogues are often compared according to receptor affinity, efficacy and selectivity rather than simply by sequence similarity.

Receptor selectivity

MC1R is strongly associated with melanocyte biology and melanin synthesis, while MC2R is the ACTH receptor of the adrenal cortex. MC3R and MC4R are prominent in central nervous-system and metabolic research, and MC5R is expressed in several peripheral tissues. Most melanocortin receptors couple primarily to Gs, increasing cyclic AMP, but cellular context can add additional signalling layers. Small sequence changes can materially alter receptor preference, which is why receptor-panel data are more informative than broad descriptions such as “a melanocortin peptide.”

KPV as a fragment

KPV, the tripeptide Lys-Pro-Val, is derived from the C-terminal region of alpha-MSH and is discussed in inflammatory and mucosal research. Literature has reported effects on NF-kappaB-related signalling and inflammatory mediators in cell and animal models, sometimes without classical melanocortin receptor dependence. Its short length and distinct pharmacology make it a useful example of how a fragment may retain selected biological properties without reproducing the full receptor profile of its parent peptide.

Semax and Selank

Semax and Selank belong to a different neuropeptide research tradition, much of it originating in Russia. Semax is derived from an ACTH fragment but was designed to minimise classical hormonal activity. Published studies have examined neurotrophin-related gene expression, monoamine systems, oxidative stress and learning or ischaemia models. Selank is derived from a tuftsin-related sequence and has been investigated in GABAergic, serotonergic and immune-related models. Some papers report changes in BDNF expression or neurotransmitter-related genes. Independent replication outside the originating literature is more limited than for established receptor systems.

LL-37 and membrane biology

LL-37 is different again. It is a 37-residue human cathelicidin antimicrobial peptide, produced as part of innate immune defence. Its amphipathic structure allows interaction with microbial membranes, while a broader literature investigates immunomodulatory, chemotactic and epithelial effects. Because membrane-active peptides can show concentration-dependent nonspecific effects in vitro, mechanistic studies require careful controls for cytotoxicity, ionic conditions and cell type.

No single neuropeptide mechanism

These examples illustrate why “neuropeptide” is not a single mechanistic category. Some peptides are classical GPCR ligands with well-defined receptor pharmacology; others are fragments with

partial or receptor-independent effects; still others are antimicrobial peptides whose primary physical interaction is with membranes. A high-quality review therefore states the receptor or proposed target rather than implying one shared mechanism.

Evidence and regulatory context

Evidence tiers also vary. Receptor-binding assays and engineered cell systems establish pharmacology; animal models examine integrated physiology; small human studies may explore biomarkers or outcomes; and controlled trials are needed for clinical conclusions. Regulatory status must be considered separately. In an Australian public-facing context, technical information about prescription or unapproved therapeutic goods must not be framed as consumer promotion. The scientifically useful approach is to describe receptor selectivity, experimental pathways and model limitations without dosage, administration or treatment claims. Exact sequence nomenclature should also be checked because related analogues may differ substantially in receptor affinity and experimental behaviour.

References

  • Therapeutic Goods Administration (Australia), current guidance on advertising prescription medicines and unapproved peptide products:* https://www.tga.gov.au/